Thirty-one percent of telaprevir patients who had gotten no benefit at all from previous treatments with the current hepatitis C regimen, a combination of interferon and antiviral drug ribavirin, had SVRs.
Under pressure from the FSA, the bank later realised that its original mortgage offer documents, which had been supplied to some customers, had been confusing about the extent to which such capped SVRs applied, or could be altered.